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Abstract
Background: Large clinical trials databases, developed over the course of a comprehensive clinical trial
programme, represent an invaluable resource for clinical researchers. Data mining projects sponsored by industry
that use these databases, however, are often not viewed favourably in the academic medical community because
of concerns that commercial, rather than scientific, goals are the primary purpose of such endeavours. Thus, there
are few examples of sustained collaboration between leading academic clinical researchers and industry
professionals in a large-scale data mining project. We present here a successful example of this type of
collaboration in the field of dementia.
Methods: The Donepezil Data Repository comprised 18 randomised, controlled trials conducted between 1991
and 2005. The project team at Pfizer determined that the data mining process should be guided by a diverse
group of leading Alzheimer’s disease clinical researchers called the “Expert Working Group.” After development of a
list of potential faculty members, invitations were extended and a group of seven members was assembled. The
Working Group met regularly with Eisai/Pfizer clinicians and statisticians to discuss the data, identify issues that
were currently of interest in the academic and clinical communities that might lend themselves to investigation
using these data, and note gaps in understanding or knowledge of Alzheimer’s disease that these data could
address. Leadership was provided by the Pfizer Clinical Development team leader; Working Group members
rotated responsibility for being lead and co-lead for each investigation and resultant publication.
Results: Six manuscripts, each published in a leading subspecialty journal, resulted from the group’s work. Another
project resulted in poster presentations at international congresses and two were cancelled due to resource constraints.
Conclusions: The experience represents a particular approach to optimising the value of data mining of large
clinical trial databases for the combined purpose of furthering clinical research and improving patient care. Fruitful
collaboration between industry and academia was fostered while the donepezil data repository was used to
advance clinical and scientific knowledge. The Expert Working Group approach warrants consideration as a
blueprint for conducting similar research ventures in the future.
Background
Development of any therapeutic agent requires invest-
ment in a comprehensive clinical trial programme. Over
the developmental lifespan of the drug, many large and
small studies are undertaken. All the accumulated data
are securely stored in databases. These databases repre-
sent a huge potential resource. In other industries–ran-
ging from manufacturing to marketing, travel to
banking, and telecommunications to finance–data
mining, the nontrivial extraction of implicit, previously
unknown patterns and relationships from data, is a
highly valued enterprise [1]. Independent, not-for-profit
organisations such as the Cochrane Collaborative http://
www.cochrane.org, and governmental bodies, such as
* Correspondence: R.W.Jones@bath.ac.uk
1RICE (Research Institute for the Care of Older People), Royal United Hospital,
Combe Park, Bath BA1 3NG, UK
Full list of author information is available at the end of the article
Jones et al. Trials 2011, 12:233
http://www.trialsjournal.com/content/12/1/233 TRIALS
© 2011 Jones et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.the Agency for Healthcare Research and Quality http://
www.ahrq.gov/research, provide excellent examples of
thoughtfully constructed and expertly executed data
mining research of clinical trial data.
There are, however, few examples of attempted or suc-
cessfully sustained collaboration between leading academic
clinical researchers and industry professionals in such an
effort. To the best of our knowledge, we present here the
first example of large-scale, extended collaboration of this
type in the field of dementia. This article describes how
one drug development team, in partnership with key ther-
apy area experts, used their database of clinical trials of
donepezil, a symptomatic treatment for patients with Alz-
heimer’s disease (AD), to address questions beyond the
scope of the original studies. This collaboration, titled the
“Donepezil Expert Working Group project,” resulted in
numerous publications addressing important clinical and
scientific questions concerning AD and its treatment.
Methods
Background
Donepezil–E2020; (R, S)-I-benzyl-4[(5,6-dimethoxyl-
indanon)-2-yl]-methyl piperidine hydrochloride–is a
piperidine-based derivative, chemically distinct from the
other cholinesterase inhibitors (ChEIs). Developed speci-
fically for the treatment of AD, donepezil is a highly
selective, reversible, noncompetitive inhibitor of acetyl-
cholinesterase (AChE). Donepezil, marketed under the
t r a d en a m eA r i c e p t
® by its developer Eisai and partner
Pfizer, received approval from the US Food and Drug
Administration (FDA) for treatment of mild to moderate
AD in November 1996 and is now approved in over 50
countries for this indication. The indication was
expanded to include severe AD in October 2006 in the
United States and in August 2007 in Japan.
The Donepezil AD Database
The donepezil data repository comprises primarily US Pfi-
zer and US Eisai clinical trial data from phase 2, phase 3
and phase 4 trials. In total, the database contains 27 inte-
grated AD studies (23 in patients with mild/moderate AD,
one in patients with moderate to severe AD and three in
patients with severe AD), including 18 double-blind, pla-
cebo-controlled trials, four open-label extension studies,
two clinical experience trials, and three others. Data for
more than 6000 unique patients, treated with donepezil
for up to 5 years, are contained in the repository [2-7].
Table 1 displays summary information for all 18 ran-
domised, controlled trials, which comprised the data
base for the data mining project.
The Expert Working Group
The project was initiated by Pfizer donepezil clinical
teams. The rationale for the project was to take
advantage of the potential of the AD database to address
important disease- and treatment-related questions that
individual trials do not. The main objectives of the pro-
ject were to identify a set of clinical questions that
could be addressed by data mining, to prioritise the
potential projects and determine which ones to pursue
and to carry out these projects with the intention of
presenting the findings at major congresses and publish-
ing them in leading peer-reviewed academic journals.
The donepezil team at Pfizer agreed that the data
mining process should be guided throughout by a
diverse group of leading AD clinical researchers, which
was termed the “Expert Working Group” or EWG.
Experts were chosen because of their knowledge of the
therapeutic area, familiarity with clinical trial methodol-
ogy and outcome measurement, participation in some of
the trials sponsored by Pfizer and/or Eisai and willing-
ness to participate actively in the EWG programme.
After a list of potential EWG faculty members was
developed, invitations were extended and a group
assembled. The group was specifically chosen to repre-
sent the global nature of the AD clinical trial pro-
gramme, and was small enough to facilitate optimal
group cohesion and functioning.
The EWG was officially established in September 2005
at a meeting in Rome, Italy; the five initial faculty mem-
bers of the EWG were Jeffrey Cummings (JC), Howard
Feldman (HF) (who left in 2008 after taking an industry
position), Roy Jones (RJ), Gunhild Waldemar (GW) and
David Wilkinson (DW). Based on questions the group
developed at this inaugural meeting, the Chair (RJ) and
faculty members recommended two additional partici-
pants, Serge Gauthier (SG) and Oscar Lopez (OL), who
joined subsequently. Geographically, the experts were
based in the United Kingdom (RJ, DW), Denmark
(GW), Canada (SG, HF), and the United States (JC, OL).
Then, as now, all were professors, clinicians and
researchers in the field of AD and dementia. Research
interests of group members included clinical trials of
drugs for AD and other dementias, immunotherapy for
AD, neuropsychiatric and behavioural symptoms in AD,
early and prodromal AD, brain structure and imaging,
and genetics. Collectively, they had published more than
1000 papers on dementia and related issues.
T h ec o r eg o a lo ft h eE W Gw a st oi n v e s t i g a t ea s p e c t s
of AD or its treatment that were insufficiently addressed
by the single studies but that could potentially be
addressed using the clinical trial database. In order to
accomplish this, Pfizer agreed to provide unfettered
access to the data repository for the EWG members. In
practice, this meant that relevant data tables and sum-
maries were provided upon request with no restrictions
(EWG members did not actually have direct access to
the data repository, primarily due to its unwieldy size
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regularly to discuss the data, identify gaps in under-
standing or knowledge of AD that were currently of
interest in the academic and clinical communities that
might lend themselves to investigation using these data
and suggest novel or innovative analyses that could
potentially address these questions. Seven Eisai/Pfizer
clinicians and three statisticians participated in the
Table 1 Donepezil AD data repository summary (randomised, controlled trials only)
Study
identifier
Phase Disease
stage/MMSE
range
Donepezil/
placebo
dose, mg
Duration
(weeks)
Study objective for
donepezil
Total patient number
(donepezil + placebo)
Cognitive
efficacy
measure
Period of
study
EWG
study*
201 [8] 2 Mild to
moderate/
10-26
1, 3, 5 12 Initial study of efficacy
and safety
150 ADAS-cog
MMSE
1991-1992 1, 3, 5
301 [9] 3 Mild to
moderate/
10-26
5, 10 12 Pivotal study of efficacy
and safety (USA)
476 ADAS-cog
MMSE
1993-1994 1, 5
302 [9] 3 Mild to
moderate/
10-26
5, 10 24 Pivotal study of efficacy
and safety (USA)
471 ADAS-
cogMMSE
1993-1994 1, 2, 5
304 [10] 3 Mild to
moderate/
10-26
5, 10 24 Pivotal study of efficacy
and safety (Europe)
816 ADAS-cog 1994-1996 1, 3, 5
134 [11] 2 Mild to
moderate/
10-26
3, 5 12 Efficacy and safety
(Japan)
190 ADAS-cog 1994 5
161 [12] 3 Mild to
moderate/
10-26
5 24 Efficacy and safety
(Japan)
268 ADAS-cog 1996-1999 1, 5
203 [13] 2 Mild to
moderate/
10-26
10 24 Effects on regional brain
glucose metabolism
28 ADAS-cog 1996-1997 1, 5
204 [14] 2 Mild to
moderate/
10-26
10 24 Effects on hippocampal
volume and neuron
integrity
67 ADAS-cog 1996-1997 1, 5
205 [15] 2 Mild to
moderate/
10-26
10 52 Effects on visuospatial
awareness
11 MMSE 1996-1997 1, 5
306 [11] 3b 10 12 ApoE subtype and
response
38 MMSE 1997-1998 1, 5
311 [16] 3b Mild to
severe/5-26
10 24 Efficacy and safety in
nursing home patients
208 MMSE 1996-1997 1, 3, 5
312 [17] 3b Mild to
moderate/
12-20
10 54 Preservation of function 431 MMSE 1996-1997 1, 3, 5
324 [18] 3b Moderate to
severe/5-18
10 24 Efficacy and safety in
moderate to severe AD
290 MMSE, SIB 1996-1998 1, 2, 3,
4, 5, 6
33301 3b Mild to
moderate/
18-26
10 12 Effect on attention 296 1997
96001
[19]
3b Mild to
moderate/
10-26
10 52 1-year DB efficacy and
safety
286 MMSE 1997 1, 2, 3,
5, 6
231 [20] 4 Severe/1-12 10 24 Efficacy and safety in
severe AD
343 SIB 2001-2005 4
315 [21] 4 Severe/1-12 5, 10 24 Efficacy and safety in
severe AD (Japan)
248 SIB 2002-2005 4
1017 [22] 4 Severe/1-10 10 24 Efficacy and safety in
severe AD
302 SIB 2002-2004 4
*1 = Jones RW et al [2]; 2 = Wilkinson D et al [3]; 3 = Gauthier S et al [4]; 4 = Cummings J et al [5]; 5 = Lopez O et al [6]; 6 = Waldemar G et al [7].
MMSE = Mini-Mental State Examination, EWG = Expert Working Group, ADAS-cog = Alzheimer’s Disease Assessment Scale-cognitive subscale, ApoE =
apolipoprotein E, SIB = Severe Impairment Battery, AD = Alzheimer’s disease, DB = double blind.
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medical communications agency provided logistical and
editorial support for EWG meetings, congress presenta-
tions and manuscript development.
EWG Activities
At the first EWG meeting, the group discussed numer-
ous investigations that could be carried out using the
data repository for the following three general cate-
gories: (1) the nature of AD; (2) treatment with done-
pezil; and (3) clinical trial methodology. In total, eight
analyses were identified and prioritised by the EWG as
worthy of study. Two of these analyses with the lowest
level of interest were not carried out because of
resource constraints. As each research question was
identified, various analyses were suggested and
evaluated.
For each project, a lead and co-lead academic clinical
researcher were identified. Although all EWG members
participated in all projects, it was important to assign
primary responsibility for each of the individual projects
to specific members. A detailed statistical analysis plan
was drafted, distributed to the EWG members and dis-
cussed via teleconference and email, resulting in a fina-
lised set of analyses to be undertaken. Results of all
analyses, including generated data tables and figures,
were shared with all group members; decisions regard-
ing which investigations to pursue further were taken by
consensus of the EWG group. Subsequent publication
development was also determined by EWG members.
Authorship was determined by level of individual inter-
est and participation as well, so not all EWG members
were authors on every manuscript.
O v e rt h ec o u r s eo f4y e a r s ,t h eg r o u pm e ts i xt i m e s
(Rome, Italy, November 2005; Glasgow, UK, September
2006; London, UK, November 2007; Hong Kong, China,
February 2008; Chicago, IL, USA, July 2008; New York,
NY, USA, via WebEx, April 2009), often in conjunction
with a major international AD meeting. Leadership was
provided by the Clinical Development team leader, sup-
ported by the scientific lead at the medical communica-
tions agency. Members of the group rotated
responsibility for being lead and co-lead for each of the
separate investigations and resultant publications. All
members of the EWG received remuneration (honor-
aria) from Pfizer Inc for their participation in the EWG
meetings, but not for time devoted to manuscript
development.
Results
Six published manuscripts resulted from the work of the
EWG. Each manuscript focused on a different topic and
had its own unique selection criteria for included studies
(Table 2).
Understanding changes in placebo populations over time
The database was used to compare the rates of cognitive
decline as measured by the Mini-Mental State
Table 2 EWG project summary
Project title RCTs
included
(n)
Selection criteria n Citation
Total Donepezil Placebo
Rates of cognitive change in AD: observations
across a decade of placebo-controlled clinical
trials with donepezil
13 Baseline MMSE scores between 10 and 26
Received placebo
3403 NA 3403 [2]
Effectiveness of donepezil in reducing clinical
worsening in patients with mild to moderate AD
3 Baseline MMSE scores between 10 and 26
Duration of at least 24 weeks
Available patient-level data for cognitive,
global and functional assessments
906 518 388 [3]
Predicting cognitive decline in AD: an integrated
analysis
14 Baseline and end-of-study (12- or 24-week)
data on cognition, (MMSE and/or ADAS-cog)
3748 2238 1510 [6]
Effect of donepezil on emergence of apathy in
mild to moderate AD
2 MMSE scores between 10 and 26
At least 24 weeks’ treatment duration
Individual patient-level behavioural data
using the NPI available
490 241 249 [7]
Effects of donepezil on activities of daily living:
integrated analysis of patient data from studies in
mild, moderate and severe AD
6 Available post-baseline functional data
collected using at least 1 ADL scale as
defined in the original study protocols
2194 1268 926 [4]
Effect of donepezil on cognition in severe AD: a
pooled data analysis
4 Available SIB data at both baseline and at
study end
904 481 423 [5]
RCTs = randomised, controlled trials, AD = Alzheimer’s disease, MMSE = Mini-Mental State Examination, ADAS-cog = Alzheimer’s Disease Assessment Scale-
cognitive subscale, NPI = Neuropsychiatric Inventory, ADL = activity of daily living, SIB = Severe Impairment Battery.
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Assessment Scale-cognitive subscale (ADAS-cog) in pla-
cebo-treated patients enrolled in trials with start dates
between 1990 and 1994 (Group 1) versus those enrolled
in trials with start dates between 1996 and 1999 (Group
2) (Table 1) [2].
The major finding was that at 24 weeks, placebo-trea-
t e dp a t i e n t sf r o mG r o u p2( t h o s ee n r o l l e di nt r i a l s
beginning after 1995) had a significantly slower rate of
decline than those in Group 1 (participants in trials
beginning prior to 1995). Thus, over the 10 years of the
donepezil clinical trial programme, placebo groups,
which were expected to remain similar, showed slower
rates of cognitive decline in more recent trials compared
with older trials. This finding suggests that the start
date of AD clinical trials may need to be considered as
an important variable when comparing study results and
that the duration of future trials may need to be
extended to account for the slower rate of cognitive
decline in the placebo group.
Reconceptualising treatment effect as a reduction in
clinical decline
AD is a disease of unremitting deterioration in cogni-
tion and the ability to perform the tasks of everyday
living. Therefore, it is important to recognise that a
reduction in the rate of decline is a positive treatment
outcome, even if no improvement relative to baseline
occurs. In addition, identifying clinical characteristics
associated with more rapid decline may be helpful in
teasing out treatment effects. Thus, two studies were
c o n c e i v e dt oe x p l o r et h en a t u r eo fd e c l i n ei np a t i e n t s
with AD and the effect of donepezil treatment on clin-
ical decline.
The first examined whether patients receiving donepe-
zil treatment had “reduced worsening” (operationally
defined by group consensus) compared with placebo [3].
Data on cognition, global change and function were
available from all patients at baseline and end point for
the three studies used in this analysis (Table 1). Clinical
worsening at Week 24 of the studies was assessed using
three sets of criteria: decline in cognition only (COG);
decline in cognition plus global rating (COG + G); and
decline in cognition, global rating and functional assess-
ment (COG + G + F).
The main finding of the analyses was that significantly
more placebo patients met the prespecified criteria for
all three definitions of clinical worsening (COG, COG +
G, COG + G + F) than donepezil-treated patients,
including after stratification by baseline severity. This
analysis demonstrated the impact of treatment in redu-
cing decline in cognition, global ratings and function
(activities of daily living; ADL), and provides support for
this alternative measure of treatment effectiveness. This
has implications for future study design and for the
assessment of treatment success.
In the second study focusing on the theme of decline,
in which 14 of 18 studies were included (Table 1), the
goal was to identify baseline demographic or illness
characteristics associated with more rapid cognitive
decline and to determine whether donepezil treatment
had an impact on the rate of decline in the subgroup of
patients with rapid decline [6]. Factors shown previously
to influence cognitive deterioration were assessed for
their ability to predict more rapid cognitive decline.
Patients were divided into “fast decliners” and “slow
decliners” according to two criteria. Criterion 1 was
based on reported average annual rates of cognitive
decline in untreated AD patients; Criterion 2 utilised
the pooled placebo population from the included stu-
dies, classifying patients into three equally sized groups
(tertiles) according to their observed change in MMSE
or ADAS-cog scores over the 12- or 24-week trials.
The key findings were as follows: variables that were
significantly associated with fast cognitive decline were
younger age, poorer cognitive and/or behavioural status
at baseline and absence of diabetes. Treatment with
donepezil reduced the odds of a fast decline in MMSE
by 39% to 52% and in ADAS-cog by 57% to 63%. These
results provided supportive evidence with respect to
some factors previously associated in the literature with
faster cognitive decline. They also demonstrated treat-
ment effects in terms of reducing the rate of decline.
Exploring AD symptom domains
The EWG recognised “apathy” as one of the early and
often persistent cardinal symptoms of the disease, a
symptom that caregivers rate as reducing the quality of
life of the patient with AD [23]. The EWG was inter-
ested in understanding the natural history and treatment
response of this symptom in comparison to other beha-
vioural symptoms characteristic of AD [7]. To increase
clinical relevance, a milestone (categorical) approach
was used, rather than comparing group means on a con-
tinuous measure. A clinical behavioural milestone was
defined as the first emergence post baseline of a Neu-
ropsychiatric Inventory (NPI) item composite score (fre-
quency × severity) ≥ 3 for that behaviour. Differences in
time to milestone for apathy and other NPI-rated beha-
viours were assessed in both placebo- and donepezil-
treated groups. Just two studies were included because
the NPI was not widely utilised in donepezil clinical
trials (Table 1).
Apathy was the NPI item with the highest proportion
of patients having a composite score ≥ 3 at baseline,
roughly 50%. Time-to-event analysis demonstrated a sig-
nificant delay in reaching the clinical milestone for
apathy in patients treated with donepezil compared with
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was also noted for aberrant motor activity (P = 0.04);
results for the other NPI items were not significant.
This analysis confirmed prior reports of the clinical
course of apathy in AD [24] and provided preliminary
evidence that ChEI treatment may delay its onset or
exacerbation. In addition, the analysis found that depres-
sion (as an NPI item) showed a markedly different pat-
tern than apathy, suggesting that apathy is not primarily
an epiphenomenon of depression.
Standardising various functional scales
In AD clinical research, as well as that of numerous
other chronic conditions, a variety of rating scales are
used to measure daily functioning. Consequently, results
are often not comparable across studies. In an ideal
world, one test scale would be used consistently across
trials. One way to develop such a “standardised func-
tional scale” is to systematically integrate elements of
existing scales. The EWG sought to employ the donepe-
zil clinical trials database to pursue this goal. Seconda-
rily, pooling functional outcome data was used to better
characterise the details of functional decline in AD and
the impact of treatment [4].
For this analysis, six randomised, double-blind pla-
cebo-controlled studies of 12 (one study) or 24 weeks’
duration were selected based on availability of post-
baseline functional data (Table 1). Individual items from
the nine ADL scales used in these studies were mapped
to a standardised functional scale comprising 12
domains–six basic and six instrumental. Individual items
from each scale were mapped to the new standardised
scale by the EWG statistician (RZ) and scores were
transformed to a 0-100 scale. External validation of item
mapping by a recognised expert in the field of functional
assessment yielded a concordance rate of 90.8%, sug-
gesting that the process was highly reliable. Patient data
from the six original trials (2177 patients with MMSE
scores between 5 and 26) were then scored using the
new standardised scale.
Donepezil treatment was associated with significantly
less worsening than placebo on change from baseline to
end of study for five items of the standardised scale (P <
0.05), and numerically less worsening on 11 of the 12
standardised items. Dividing the patients into subpopu-
lations with mild (MMSE 18-26), moderate (MMSE 10-
1 7 )a n ds e v e r e( M M S E5 - 9 )A Ds h o w e dt h a tt r e a t m e n t
with donepezil provided the most functional benefit to
those in the moderate phase of the disease.
This work provided an example of a method to stan-
dardise multiple functional scale scores, allowing for
comparison of functional outcomes between studies
employing different rating scales and/or pooling of func-
tional data from multiple studies to increase statistical
power. It also provided additional supportive evidence
for the benefit of ChEI treatment on daily functioning,
particularly in patients with AD of moderate severity.
Investigating the utility of treatment in patients with
severe AD
The final EWG project focused on the controversial
question of the utility of treating patients with severe
AD with ChEIs. Licensing of ChEIs for severe AD
remains inconsistent across countries, and the clinical
meaningfulness of the drugs’ use in this population has
been questioned [25]. The EWG believed that part of
this inconsistency was a consequence of the poor per-
formance of standard instruments, such as the MMSE
or ADAS-cog, in capturing the natural history of the
disease and the effects of treatment in this patient popu-
lation. For this reason, studies using the Severe Impair-
ment Battery (SIB), which has been shown to track
change over time in patients with late-stage AD [26],
were selected (Table 1). These analyses sought to better
explain the performance of the SIB in clinical trials and
to examine in detail the impact of treatment with done-
pezil in this population [5]. For the analysis, patients
were stratified by baseline MMSE scores into four
groups: MMSE score 1-5 (most severe), MMSE score 6-
9 (severe), MMSE score 10-12 (early severe) and MMSE
score 13-17 (moderate).
T h em a i nf i n d i n go ft h i ss t u d yw a sas i g n i f i c a n tl e a s t
squares (LS) mean difference in SIB total scores from
baseline to 24 weeks between those treated with done-
pezil and those receiving placebo (6.22 [P < 0.0001,
Cohen’s d, 0.53]). Treatment-placebo LS mean differ-
ences were statistically significant for all baseline sever-
i t ys t r a t a( r a n g e ,P = 0.0251 to P < 0.0001; Cohen’s d,
0.41-0.66) and for seven of nine SIB domains (range, P
=0 . 0 0 5 6t oP < 0.0001; Cohen’s d, 0.17-0.48). Patients
receiving donepezil showed improvement above baseline
in eight of nine domains, those receiving placebo wor-
sened in all domains. The clinical meaningfulness of
these improvements was demonstrated with significant
positive correlations between change in SIB scores and
change in functional and global measures.
Discussion
In this article we seek to share, in broad outline, the
organisational process usedb yt h ed o n e p e z i lE W Gf o r
identifying scientific questions of interest and carrying
out exploratory research using a large clinical trial data-
base. We then illustrate the value of this approach for
elucidating useful information about AD and the impact
of donepezil treatment by summarising the EWG’s pub-
lications output. Through this process, academic and
clinical researchers gained access to a vast database,
important questions concerning AD and its treatment
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port research beyond narrow regulatory goals.
There were numerous clinically relevant findings from
the EWG studies, including extending knowledge of pla-
cebo group outcomes in AD clinical trials by document-
ing a trend towards slower decline from 1990 to 2000;
illustrating the value of using “reduced worsening” (or
“less than expected decline”) as an outcome measure of
treatment effectiveness in AD studies; providing evi-
dence that the onset/exacerbation of apathy can be
delayed by AChEI treatment; demonstrating a method
for standardisation of multiple functional scales,
enabling improved comparisons across studies and pool-
ing of functional data from multiple studies; and using
the SIB to document improvement in patients with
severe AD. Each paper either provided supportive evi-
dence for existing hypotheses concerning disease pro-
gression and/or response to treatment or was regarded
as hypothesis generating and helped to build the case
for additional prospective research on new topics.
T h es i z eo ft h ed a t a b a s ew a s a great asset for these
studies, as data could be divided into groups that all
retained sufficient numbers of patients for meaningful
statistical comparisons. For example, in the severe AD
manuscript [5], patients with severe AD were subdivided
into three groups according to their MMSE score; in the
manuscript investigating rapid decline [6], patients were
stratified into fast and slow decliners using two different
sets of criteria. The extended span of time covered by
the database was critical in being able to detect a change
in the performance of placebo groups from 1990 to
2000.
There were several key strengths of the EWG
approach that differentiate it from routine pharmaceuti-
cal industry data mining research. Most importantly, the
investigations were suggested, evaluated and led by lead-
ing clinical researchers in the field of AD and dementia,
not by the company. Although this was a partnership
between professionals in industry and academia, it was
the former who provided the resources while the latter
guided the process. Second, the company’s data were
extensively shared with EWG members. Third, the med-
ical communications agency was treated as a true part-
ner in the collaboration, which enhanced the
organisational effectiveness and publications productivity
of the group as a whole.
Despite the strengths of the project, there are inherent
limitations to all data pooling research that also apply to
the work of the EWG. For example, large databases can
sometimes assist in identifying statistically significant
outcomes that are not clinically meaningful. The EWG
was cognisant of this threat and used a variety of
approaches to confirm the clinical importance of the
results. Also, by definition, all of the analyses were post-
hoc and therefore exploratory. In addition, all involved
pooling of data from trials that were conducted accord-
ing to different protocols, in different places, and at dif-
f e r e n tt i m e s .T h er e p o s i t o r yd a t aw e r el i m i t e dt o
company-sponsored donepezil trials, so studies on com-
parative effectiveness were not possible and investigator-
initiated trials in other populations were not included.
Finally, there is always a potential bias based on the par-
ticular experts selected and the topics chosen (and not
chosen) for analysis. However, the size and diversity of
the group were intended to minimise this source of bias.
There are certain aspects of the EWG process that
could be improved in future projects of this type. First,
the delay between completion of clinical trials and
initiation of the data mining effort could be shortened.
For example, a project similar to the EWG could be
initiated prior to the completion of the entire clinical
trial programme, particularly if subsequent clinical trials
focus on a different stage of the disease, or a different
manner of therapy (e.g. add-on vs. monotherapy), than
the component of the trial programme already com-
pleted. With respect to the EWG project, during the 5
years between completion of the randomised, controlled
trials in mild to moderate AD and the first meeting of
the EWG, three large clinical trials in severe AD and a
number of open-label studies were all being conducted,
which limited the capacity of the company to begin a
major new project. Second, although the final EWG
meeting did take place via Web conferencing, this tech-
nology is continually improving and could be utilised
more extensively in addition to, as well as in place of,
live meetings.
Use of clinical trial databases is becoming more
important because of concerns about patient safety and
the initiative to study comparative effectiveness of treat-
ments. As such, it will require cooperation among phar-
maceutical companies, and between pharmaceutical
companies and regulatory agencies, particularly the US
FDA. In this regard, the FDA has launched a new pro-
ject, called Janus, which is currently gaining momentum.
Janus will provide a hub for integrating data within the
FDA to support regulatory decisions and pharmacovigi-
lance. The goal is to facilitate standardisation in acquisi-
tion and analysis of study data, allowing integration of
clinical trial data and postmarketing safety data to
improve public health and patient safety. The Janus
repository was created during 2010, and existing data
are being converted into the standard format during
2011. This project will harness the capacity of large
study data repositories to answer questions about care
and to enable pilot studies of comparative effectiveness
[27]. Two other examples of effective data sharing are
the Critical Path Institute’s Coalition Against Major Dis-
eases database of negative AD trials (C-Path Online
Jones et al. Trials 2011, 12:233
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Neuroimaging Initiative (ADNI, http://www.adni-info.
org). In this regard, the EWG process is a stepping
stone towards much deeper and wider degrees of part-
nership and collaboration in the service of patient safety
and treatment effectiveness.
Conclusion
The EWG experience represents a particular approach
to optimising the value of data mining of large clinical
trial databases for the combined purpose of furthering
clinical research and improving patient care. Fruitful
collaboration between industry and academia was fos-
tered while the donepezil data repository was used to
advance clinical and scientific knowledge. The EWG
approach warrants consideration as a blueprint for con-
ducting similar research ventures in the future.
Acknowledgements
In the preparation of this manuscript, editorial support was provided by B.
Kadish, MD, of PAREXEL and was funded by Pfizer Inc.
Yikang Xu, PhD, of Pfizer Inc helped to design the studies, analyse the data
and review initial drafts of this manuscript. Yikang Xu died on February 6,
2011. We value his contributions to this manuscript and mourn the loss of
our esteemed colleague.
Author details
1RICE (Research Institute for the Care of Older People), Royal United Hospital,
Combe Park, Bath BA1 3NG, UK.
2Memory Assessment and Research Centre,
Moorgreen Hospital, Southampton, UK.
3Alzheimer’s Disease Research
Center, Departments of Neurology and Psychiatry, University of Pittsburgh,
Pittsburgh, PA, USA.
4Cleveland Clinic, Lou Ruvo Center for Brain Health, Las
Vegas, NV, USA.
5Memory Disorders Research Group, Dept. of Neurology,
Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
6Pfizer Global Pharmaceuticals, Pfizer Inc, New York, NY, USA.
7McGill Center
for Studies in Aging, Douglas Mental Health University Institute, Douglas
Hospital, Verdun, Quebec, Canada.
Authors’ contributions
All authors contributed equally to this manuscript, and to the analyses and
publications described in the manuscript. Each author participated in the
concept and design of this article, reviewed each draft and provided critical
intellectual content and approved the final manuscript.
Competing interests
The analyses described herein result from a constituted expert working
group initiated and funded by Eisai Inc. and Pfizer Inc. Drs Richard Zhang,
Yikang Xu and Joan Mackell are employees of Pfizer Inc. All other authors
report having received consultancy and/or speaker fees from Pfizer Inc and
each author also received honoraria for their participation in the expert
working group sessions; none received any compensation for their work on
this manuscript. Dr. Cummings holds the copyright of the Neuropsychiatric
Inventory.
Received: 14 June 2011 Accepted: 26 October 2011
Published: 26 October 2011
References
1. Lee IN, Liao SC, Embrechts M: Data mining techniques applied to medical
information. Med Inform Internet Med 2000, 25(2):81-102.
2. Jones RW, Schwam E, Wilkinson D, Waldemar G, Feldman HH, Zhang R,
Albert K, Schindler R: Rates of cognitive change in Alzheimer disease:
observations across a decade of placebo-controlled clinical trials with
donepezil. Alzheimer Dis Assoc Disord 2009, 23(4):357-364.
3. Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones RW, Gauthier S,
Lopez OL, Cummings J, Xu Y, Feldman HH: Effectiveness of donepezil in
reducing clinical worsening in patients with mild-to-moderate
Alzheimer’s disease. Dement Geriatr Cogn Disord 2009, 28(3):244-251.
4. Gauthier S, Lopez OL, Waldemar G, Jones RW, Cummings J, Zhang R,
Schindler R, Schwam E: Effects of donepezil on activities of daily living:
integrated analysis of patient data from studies in mild, moderate and
severe Alzheimer’s disease. Int Psychogeriatr 2010, 22(6):973-983.
5. Cummings J, Jones R, Wilkinson D, Lopez O, Gauthier S, Waldemar G,
Zhang R, Xu Y, Sun Y, Richardson S, Mackell J: Effect of donepezil on
cognition in severe Alzheimer’s disease: a pooled data analysis. J
Alzheimers Dis 2010, 21(3):843-851.
6. Lopez OL, Schwam E, Cummings J, Gauthier S, Jones R, Wilkinson D,
Waldemar G, Zhang R, Schindler R: Predicting cognitive decline in
Alzheimer’s disease: an integrated analysis. Alzheimers Dement 2010,
6(6):431-439.
7. Waldemar G, Gauthier S, Jones R, Wilkinson D, Cummings J, Lopez O,
Zhang R, Xu Y, Sun Y, Knox S, Richardson S, Mackell J: Effect of donepezil
on emergence of apathy in mild to moderate Alzheimer’s disease. Int J
Geriatr Psychiatry 2011, 26(2):150-157.
8. Rogers SL, Friedhoff LT, the Donepezil Study Group: The efficacy and
safety of donepezil in patients with Alzheimer’s disease: results of a US
multicentre, randomized, double-blind, placebo-controlled trial. Dementia
1996, 7(6):293-303.
9. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Donepezil Study
Group: A 24-week, double-blind, placebo-controlled trial of donepezil in
patients with Alzheimer’s disease. Neurology 1998, 50(1):136-145.
10. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL,
Friedhoff LT: The effects of donepezil in Alzheimer’s disease - results
from a multinational trial. Dement Geriatr Cogn Disord 1999, 10(3):237-244.
11. Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG: Donepezil
for the symptomatic treatment of patients with mild to moderate
Alzheimer’s disease: a meta-analysis of individual patient data from
randomised controlled trials. Int J Geriatr Psychiatry 2004, 19(7):624-633.
12. Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M,
Nishimura T: Clinical efficacy and safety of donepezil on cognitive and
global function in patients with Alzheimer’s disease. A 24-week,
multicenter, double-blind, placebo-controlled study in Japan. E2020
Study Group. Dement Geriatr Cogn Disord 2000, 11(6):299-313.
13. Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, Jewart RD,
Hoffman JM: Donepezil HCl (E2020) maintains functional brain activity in
patients with Alzheimer disease: results of a 24-week, double-blind,
placebo-controlled study. Am J Geriatr Psychiatry 2003, 11(2):169-177.
14. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X,
Perdomo C, Ieni JR, Rogers S: Randomized, placebo-controlled trial of the
effects of donepezil on neuronal markers and hippocampal volumes in
Alzheimer’s disease. Am J Psychiatry 2003, 160(11):2003-2011.
15. Geldmacher D, Perdomo C, Pratt R: Effect of donepezil treatment on
visual attention/exploration tasks in patients with mild to moderately
severe Alzheimer’s disease: results of a pilot study [abstract]. Neurobiol
Aging 2000, 21(1S):S169..
16. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM,
Whalen E: A randomized, double-blind, placebo-controlled study of the
efficacy and safety of donepezil in patients with Alzheimer’s disease in
the nursing home setting. J Am Geriatr Soc 2001, 49:1590-1599.
17. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD,
“312” Study Group: A 1-year, placebo-controlled preservation of function
survival study of donepezil in AD patients [published erratum appears in
Neurology. 2001;57:1942]. Neurology 2001, 57(3):481-488.
18. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E: A 24-week,
randomized, double-blind study of donepezil in moderate to severe
Alzheimer’s disease. Neurology 2001, 57(4):613-620.
19. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A,
Wetterholm AL, Zhang R, Haglund A, Subbiah P, Donepezil Nordic Study
Group: A 1-year, randomized, placebo-controlled study of donepezil in
patients with mild to moderate AD. Neurology 2001, 57(3):489-495.
20. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA,
Richardson S: Donepezil preserves cognition and global function in
patients with severe Alzheimer disease. Neurology 2007, 69(5):459-469.
21. Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M,
Arimoto I, Koma H, Ohbayashi T: Donepezil treatment of patients with
Jones et al. Trials 2011, 12:233
http://www.trialsjournal.com/content/12/1/233
Page 8 of 9severe Alzheimer’s disease in a Japanese population: results from a 24-
week, double-blind, placebo-controlled, randomised trial. Dement Geriatr
Cogn Disord 2008, 25(5):399-407.
22. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL,
Jansson-Blixt C, Haglund A: Donepezil in patients with severe Alzheimer’s
disease: double-blind, parallel-group, placebo-controlled study. Lancet
2006, 367(9516):1057-1065.
23. Hoe J, Katona C, Orrell M, Livingston G: Quality of life in dementia: care
recipient and caregiver perceptions of quality of life in dementia: the
LASER-AD study. Int J Geriatr Psychiatry 2007, 22(10):1031-1036.
24. Starkstein SE, Petracca G, Chemerinski E, Kremer J: Syndromic validity of
apathy in Alzheimer’s disease. Am J Psychiatry 2001, 158(6):872-877.
25. Hogan DB: Donepezil for severe Alzheimer’s disease. Lancet 2006,
367(9516):1031-1032.
26. Wild KV, Kaye JA: The rate of progression of Alzheimer’s disease in the
later stages: evidence from the Severe Impairment Battery. J Int
Neuropsychol Soc 1998, 4(5):512-516.
27. Janus, data standard comparative effectiveness research: U S Food and
Drug Administration Web site.[http://www.fda.gov/downloads/
AdvisoryCommittees/committeesMeetingMaterials/
Scienceboardtothefoodanddrugadministration/UCM224277.pdf], Accessed
August 31, 2011.
doi:10.1186/1745-6215-12-233
Cite this article as: Jones et al.: Collaborative research between
academia and industry using a large clinical trial database: a case study
in Alzheimer’s disease. Trials 2011 12:233.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jones et al. Trials 2011, 12:233
http://www.trialsjournal.com/content/12/1/233
Page 9 of 9